drugset / Trial / NCT06774664
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in subjects with plasma cell-driven autoimmune diseases
Timeline
- Start
- 2025-01
- Primary completion
- 2027-09
- Completion
- 2029-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCTC21C | Unknown | — | Subcutaneous |